Blood thinner apixaban tested for late clots after spleen surgery
NCT ID NCT07461532
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the blood thinner apixaban can dissolve blood clots in the portal vein that develop more than a year after laparoscopic spleen surgery in people with cirrhosis. Twenty participants will take apixaban twice daily, and doctors will use ultrasound or CT scans to see if the clots shrink or disappear. If successful, patients will continue apixaban long-term to prevent recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apixaban
- What this could lead to
- If effective, apixaban could offer a safe way to dissolve late-occurring portal vein clots after spleen surgery, potentially preventing serious complications.
- What could go wrong
- This is a very small early study with only 20 participants, so results may not apply broadly. Patients must take apixaban indefinitely if it works, and bleeding risks are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Medical College
RECRUITINGYangzhou, Jiangsu, 225001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can everyday drugs shield the liver from Cirrhosis's worst threats?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Could a yellow tinge predict dangerous hospital infections?
- Muscle quality on MRI may foretell liver transplant success
- Melatonin may ease sleep and brain fog in liver disease — a trial puts it to the test
- Which vein is safer for chemotherapy ports? a trial aims to settle the debate